Join the club for FREE to access the whole archive and other member benefits.

Juergen Reess

Co-founder and CEO at Mogling Bio, Managing Director at Cellerys AG

Jürgen has over 20 years of experience in operative and strategic clinical development, most recently as the CEO and managing director of Cellerys AG.  Prior to that, he was Corporate Senior Vice President of International Project Management at Boehringer Ingelheim Human Pharma. A trained physician with a medical and doctorate degree from the University of Ulm (Germany), he is a board-certified neurologist and a leader in the pharmaceutical industry. He supervised the development, approval, and launch of numerous blockbuster therapies for autoimmune diseases, interstitial lung diseases, central nervous system disorders, and cancer, meeting milestones in nearly 100 projects across several therapy areas. Jürgen leads Mogling Bio with a high proficiency in fostering productivity and creativity in multidisciplinary teams to move the anti-stem cell aging product development forward.

Visit website: https://www.moglingbio.com/team/reess-juergen

 juergen-reess-b443468

See also: Company Mogling Bio - Biopharmaceutical company developing new treatments for rejuvenating old stem cells

Details last updated 21-Oct-2022

Juergen Reess is also referenced in the following:

Mogling Bio

Biopharmaceutical company developing new treatments for rejuvenating old stem cells

Rejuvenation Startup Summit 2024

10-May-2024 to 11-May-2024

The leading networking event for rejuvenation startups, longevity investors and translational researchers by Forever Healthy Foundation

Juergen Reess News

Reason reports back from Rejuvenation Startup Summit 2024

Reason reports back from Rejuvenation Startup Summit 2024

Fight Aging! - 13-May-2024

A great summary of 25 speakers who are in various stages of platform building, drug discovery and clinical trials

Stem cell biotech MoglinBio secures seed investment

Stem cell biotech MoglinBio secures seed investment

KIZOO Technology Ventures - 26-Oct-2022

Kizoo is focused on rejuvenation biotech so it must see potential in normalizing CDC42 activity

Reason reports back from October's Rejuvenation Startup Summit

Reason reports back from October's Rejuvenation Startup Summit

Fight Aging! - 19-Oct-2022

Some really exciting developments with quite a few in clinical trials